PBM reform scrutiny of reimbursement, rebate flow, and compensation can shift benefit conditions that determine how manufacturer-funded copay, buy-down, and support programs function at dispensing.
Pairing Tennr referral intake and documentation automation with TailorMed affordability tooling is designed to surface access barriers earlier and shorten time-to-therapy for infusion and specialty ...
Tech-enabled pharmacies reflect the reality of the GLP-1 landscape: patient success depends on more than a prescription. With ...
Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, explains which therapeutic areas will lead DTP adoption and her five-year outlook for the model. Direct-to-patient (DTP) programs are no ...
Section 232 introduces a staged tariff regime: 100% default for patented drugs/APIs/KSMs, reduced 20% with approved onshoring plans, and temporary 0% if paired with MFN pricing until 2029. Deadlines ...
Clinician-led engagement outperforms non-clinical call-center models, with “nurse ambassador” programs enabling escalation, ...
Dual BAFF/APRIL blockade targets upstream B-cell survival signaling to reduce production of galactose-deficient IgA1 and anti–Gd-IgA1 autoantibodies driving nephritogenic immune complexes. ORIGIN 3 ...
Bansi Nagji discusses the shifting science behind rare and orphan drug development, including what it takes for therapies to succeed well beyond launch. Bansi Nagji, CEO of PANTHERx Rare, explores how ...
Statutory government programs (AMP/ASP, Medicaid best price, IRA, 340B, FSS, Parts B/D) increasingly define net-revenue constraints and shape viable commercial contracting boundaries. Commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results